$NKTR NEKTAR THERAPEUTICS Insider Trading Week 32/2018
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NEKTAR THERAPEUTICS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NEKTAR THERAPEUTICS in week 32/2018.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | A | 56.90 | 26,250 | 1,493,625 | 26,250 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | A | 56.90 | 26,250 | 1,493,625 | 26,250 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | D | 58.40 | 4,883 | 285,167 | 71,265 | 76.1 K to 71.3 K (-6.41 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | D | 58.40 | 4,883 | 285,167 | 71,265 | 76.1 K to 71.3 K (-6.41 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Grant | A | 0.00 | 10,400 | 0 | 76,148 | 65.7 K to 76.1 K (+15.82 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Grant | A | 0.00 | 10,400 | 0 | 76,148 | 65.7 K to 76.1 K (+15.82 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | D | 58.40 | 8,137 | 475,201 | 180,459 | 188.6 K to 180.5 K (-4.31 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | D | 58.40 | 8,137 | 475,201 | 180,459 | 188.6 K to 180.5 K (-4.31 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Grant | A | 0.00 | 26,000 | 0 | 188,596 | 162.6 K to 188.6 K (+15.99 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Grant | A | 0.00 | 26,000 | 0 | 188,596 | 162.6 K to 188.6 K (+15.99 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | D | 58.40 | 8,207 | 479,289 | 113,059 | 121.3 K to 113.1 K (-6.77 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | D | 58.40 | 8,207 | 479,289 | 113,059 | 121.3 K to 113.1 K (-6.77 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Grant | A | 0.00 | 26,000 | 0 | 121,266 | 95.3 K to 121.3 K (+27.29 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Grant | A | 0.00 | 26,000 | 0 | 121,266 | 95.3 K to 121.3 K (+27.29 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | A | 56.90 | 37,500 | 2,133,750 | 37,500 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | A | 56.90 | 37,500 | 2,133,750 | 37,500 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | D | 58.40 | 5,946 | 347,246 | 85,723 | 91.7 K to 85.7 K (-6.49 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | D | 58.40 | 5,946 | 347,246 | 85,723 | 91.7 K to 85.7 K (-6.49 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Grant | A | 0.00 | 15,000 | 0 | 91,669 | 76.7 K to 91.7 K (+19.56 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Grant | A | 0.00 | 15,000 | 0 | 91,669 | 76.7 K to 91.7 K (+19.56 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | A | 56.90 | 151,250 | 8,606,125 | 151,250 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | A | 56.90 | 151,250 | 8,606,125 | 151,250 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 10.69 | 40,000 | 427,600 | 0 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 10.69 | 40,000 | 427,600 | 0 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | D | 58.40 | 20,389 | 1,190,718 | 264,467 | 284.9 K to 264.5 K (-7.16 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | D | 58.40 | 20,389 | 1,190,718 | 264,467 | 284.9 K to 264.5 K (-7.16 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 0.00 | 60,500 | 0 | 284,856 | 224.4 K to 284.9 K (+26.97 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 0.00 | 60,500 | 0 | 284,856 | 224.4 K to 284.9 K (+26.97 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | D | 60.08 | 40,000 | 2,403,200 | 224,356 | 264.4 K to 224.4 K (-15.13 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | D | 60.08 | 40,000 | 2,403,200 | 224,356 | 264.4 K to 224.4 K (-15.13 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 10.69 | 40,000 | 427,600 | 264,356 | 224.4 K to 264.4 K (+17.83 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 10.69 | 40,000 | 427,600 | 264,356 | 224.4 K to 264.4 K (+17.83 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | D | 58.40 | 6,701 | 391,338 | 83,258 | 90 K to 83.3 K (-7.45 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | D | 58.40 | 6,701 | 391,338 | 83,258 | 90 K to 83.3 K (-7.45 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Grant | A | 0.00 | 26,000 | 0 | 89,959 | 64 K to 90 K (+40.65 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Grant | A | 0.00 | 26,000 | 0 | 89,959 | 64 K to 90 K (+40.65 %) |
| Aug 15 2018 | NKTR | NEKTAR THERAPEUTIC ... | WINGER DENNIS L | Director | Sell | S | 60.15 | 17,125 | 1,030,069 | 42,750 | 59.9 K to 42.8 K (-28.60 %) |
| Aug 15 2018 | NKTR | NEKTAR THERAPEUTIC ... | WINGER DENNIS L | Director | Sell | S | 61.04 | 17,125 | 1,045,310 | 59,875 | 77 K to 59.9 K (-22.24 %) |